How would you treat a patient with prostate cancer with de novo bone and bone marrow metastases with cytopenias?
Would you consider chemotherapy, androgen blockade or triple therapy (chemo and AR targeting)?
Answer from: Medical Oncologist at Academic Institution
Men who present with diffuse bone marrow involvement by definition have high volume de novo disease, and among the worst prognosis of all situations. Level 1 evidence now suggests that triple therapy with ADT/docetaxel and concurrent abiraterone or darolutamide (level 1), or sequential ADT/docetaxel...
Sign in or Register to read more